IL144793A0 - Process for the production of tert-butyl (e)-(6-[2[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl] (4r,6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate - Google Patents

Process for the production of tert-butyl (e)-(6-[2[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl] (4r,6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate

Info

Publication number: IL144793A0
Authority: IL; Israel
Prior art keywords: dioxan; methylsulfonyl; pyrimidin; fluorophenyl; tert
Prior art date: 1999-02-17

Application number

IL14479300A

Other languages

English (en)

Original Assignee

Astrazeneca Ab

Shionogi & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-17

Filing date

2000-02-15

Publication date

2002-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL144793(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-02-15 Application filed by Astrazeneca Ab, Shionogi & Co filed Critical Astrazeneca Ab

2002-06-30 Publication of IL144793A0 publication Critical patent/IL144793A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)

IL14479300A 1999-02-17 2000-02-15 Process for the production of tert-butyl (e)-(6-[2[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl] (4r,6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate IL144793A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9903472.0A GB9903472D0 (en)	1999-02-17	1999-02-17	Chemical process
PCT/GB2000/000481 WO2000049014A1 (en)	1999-02-17	2000-02-15	Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate

Publications (1)

Publication Number	Publication Date
IL144793A0 true IL144793A0 (en)	2002-06-30

Family

ID=10847843

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL14479300A IL144793A0 (en)	1999-02-17	2000-02-15	Process for the production of tert-butyl (e)-(6-[2[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl] (4r,6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate
IL163375A IL163375A (en)	1999-02-17	2004-08-05	Protected dihydroxy acid derivatives and processes for the preparation of an intermediate substance oxide diphenylposphine for them

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL163375A IL163375A (en)	1999-02-17	2004-08-05	Protected dihydroxy acid derivatives and processes for the preparation of an intermediate substance oxide diphenylposphine for them

Country Status (34)

Country	Link
US (2)	US6844437B1 (is)
EP (1)	EP1155015B1 (is)
JP (3)	JP2003518474A (is)
KR (1)	KR100648160B1 (is)
CN (1)	CN1145625C (is)
AR (1)	AR022600A1 (is)
AT (1)	ATE415398T1 (is)
AU (1)	AU760145B2 (is)
BR (1)	BRPI0008301B8 (is)
CA (1)	CA2362594C (is)
CL (1)	CL2003002336A1 (is)
CY (1)	CY1108733T1 (is)
CZ (1)	CZ299844B6 (is)
DE (1)	DE60040905D1 (is)
DK (1)	DK1155015T3 (is)
EE (2)	EE05531B1 (is)
ES (1)	ES2316349T3 (is)
GB (1)	GB9903472D0 (is)
HK (1)	HK1041265B (is)
HU (1)	HU229835B1 (is)
IL (2)	IL144793A0 (is)
IS (1)	IS2709B3 (is)
MX (1)	MXPA01008235A (is)
NO (1)	NO320739B1 (is)
NZ (1)	NZ513261A (is)
PL (1)	PL218518B1 (is)
PT (1)	PT1155015E (is)
RU (1)	RU2243969C2 (is)
SI (1)	SI1155015T1 (is)
SK (1)	SK286988B6 (is)
TR (2)	TR200102360T2 (is)
TW (1)	TWI285202B (is)
WO (1)	WO2000049014A1 (is)
ZA (1)	ZA200106370B (is)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9902202D0 (sv) *	1999-06-10	1999-06-10	Astra Ab	Production of aggregates
GB0003305D0 (en)	2000-02-15	2000-04-05	Zeneca Ltd	Pyrimidine derivatives
GB0011120D0 (en)	2000-05-09	2000-06-28	Avecia Ltd	Process
NL1015744C2 (nl)	2000-07-19	2002-01-22	Dsm Nv	Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
EP1417180B1 (en) *	2001-07-13	2006-12-27	AstraZeneca UK Limited	Preparation of aminopyrimidine compounds
RU2301801C2 (ru) *	2001-07-13	2007-06-27	АстраЗенека Ю-Кей Лимитед	Способ получения сульфониламинопиримидиновых соединений (варианты), промежуточные продукты и способы их получения
SK1402004A3 (sk) *	2001-08-16	2005-01-03	Teva Pharmaceutical Industries Ltd.	Spôsob prípravy vápenatých solí statinov
EP1323717A1 (en)	2001-12-27	2003-07-02	Dsm N.V.	Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en)	2002-06-17	2004-01-02	Dsm N.V.	Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en)	2002-08-13	2002-09-18	Astrazeneca Ab	Chemical process
DK1578731T3 (da) *	2002-12-16	2010-02-15	Astrazeneca Uk Ltd	Fremgangsmåde til fremstilling af pyrimidinforbindelser
GB0312896D0 (en) *	2003-06-05	2003-07-09	Astrazeneca Ab	Chemical process
US7396927B2 (en)	2003-08-28	2008-07-08	Teva Pharmaceutical Industries Ltd.	Process for preparation of rosuvastatin calcium
UY28501A1 (es) *	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
GB0321827D0 (en) *	2003-09-18	2003-10-15	Astrazeneca Uk Ltd	Chemical compounds
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
GB0324791D0 (en) *	2003-10-24	2003-11-26	Astrazeneca Ab	Chemical process
CA2546701C (en) *	2003-11-24	2010-07-27	Teva Pharmaceutical Industries Ltd.	Crystalline ammonium salts of rosuvastatin
DE602004032465D1 (de)	2003-12-02	2011-06-09	Teva Pharma	Referenzstandard zur charakterisierung von rosuvastatin
US7241800B2 (en)	2004-03-17	2007-07-10	Mai De Ltd.	Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en)	2004-03-26	2004-04-28	Avecia Ltd	Process and compounds
WO2006017357A1 (en)	2004-07-13	2006-02-16	Teva Pharmaceutical Industries Ltd.	A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
GB0427491D0 (en)	2004-12-16	2005-01-19	Avecia Ltd	Process and compounds
GB0428328D0 (en)	2004-12-24	2005-02-02	Astrazeneca Uk Ltd	Chemical process
CN100351240C (zh) *	2005-01-19	2007-11-28	安徽省庆云医药化工有限公司	瑞舒伐他汀钙的合成方法
WO2006091770A2 (en)	2005-02-22	2006-08-31	Teva Pharmaceutical Industries Ltd.	Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
WO2006100689A1 (en) *	2005-03-22	2006-09-28	Unichem Laboratories Limited	Process for preparation of rosuvastatin
US20080161560A1 (en) *	2005-04-04	2008-07-03	Pandurang Balwant Deshpande	Process for Preparation of Calcium Salt of Rosuvastatin
HU227120B1 (hu) *	2005-05-26	2010-07-28	Richter Gedeon Nyrt	Eljárás rosuvastatin kalciumsójának elõállítására új intermediereken keresztül
CA2611920C (en) *	2005-06-24	2015-05-05	Lek Pharmaceuticals D.D.	Process for preparing pure amorphous rosuvastatin calcium
JP5146965B2 (ja) *	2005-06-24	2013-02-20	レツク・フアーマシユーテイカルズ・デー・デー	不純物を含まない非晶質ロスバスタチンカルシウムの調製方法
GB0514078D0 (en) *	2005-07-08	2005-08-17	Astrazeneca Uk Ltd	Chemical process
US8354530B2 (en)	2005-07-28	2013-01-15	Lek Pharmaceuticals d. d	Process for the synthesis of rosuvastatin calcium
KR20070062996A (ko)	2005-08-16	2007-06-18	테바 파마슈티컬 인더스트리즈 리미티드	결정성 로수바스타틴 중간체
CN100436428C (zh) *	2005-08-22	2008-11-26	鲁南制药集团股份有限公司	瑞舒伐他汀及其盐的制备方法
CN100352821C (zh) *	2005-08-22	2007-12-05	鲁南制药集团股份有限公司	一种瑞舒伐他汀钙中间体的制备方法
HUE027872T2 (en) *	2006-05-03	2016-11-28	Msn Laboratories Private Ltd	A novel process for statins and their pharmaceutically acceptable salts
ES2567171T3 (es)	2006-10-09	2016-04-20	Msn Laboratories Private Limited	Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
WO2008053334A2 (en)	2006-10-31	2008-05-08	Aurobindo Pharma Limited	An improved process for preparing rosuvastatin calcium
TW200831469A (en) *	2006-12-01	2008-08-01	Astrazeneca Uk Ltd	Chemical process
WO2008072078A1 (en)	2006-12-13	2008-06-19	Aurobindo Pharma Limited	An improved process for preparing rosuvastatin caclium
AU2008212622B2 (en)	2007-02-08	2011-01-27	Aurobindo Pharma Limited	An improved process for preparation of rosuvastatin calcium
EP2032586A2 (en)	2007-04-18	2009-03-11	Teva Pharmaceutical Industries Ltd.	A process for preparing intermediates of hmg-coa reductase inhibitors
EP2178846A1 (en)	2007-07-12	2010-04-28	Teva Pharmaceutical Industries Ltd.	Rosuvastatin intermediates and their preparation
EP2181089A2 (en)	2007-08-28	2010-05-05	Ratiopharm GmbH	Process for preparing pentanoic diacid derivatives
CN101376647B (zh) *	2007-08-31	2010-12-08	中山奕安泰医药科技有限公司	一种用于合成瑞舒伐他汀中间体及瑞舒伐他汀的合成方法
WO2009143776A1 (zh)	2008-05-27	2009-12-03	常州制药厂有限公司	瑞舒伐他汀钙盐的制备方法及其中间体
PT2309992T (pt)	2008-06-27	2018-01-22	Krka Tovarna Zdravil D D Novo Mesto	Composição farmacêutica compreendendo uma estatina
EP2138165A1 (en)	2008-06-27	2009-12-30	KRKA, tovarna zdravil, d.d., Novo mesto	Pharmaceutical composition comprising a statin
WO2010029561A1 (en) *	2008-09-09	2010-03-18	Biocon Limited	A process for preparation of rosuvastatin acetonide calcium
US8394956B2 (en) *	2008-09-30	2013-03-12	Aurobindo Pharma Ltd.	Process for preparing pyrimidine propenaldehyde
EP2351762B1 (en) *	2008-10-20	2013-10-16	Kaneka Corporation	NOVEL PYRIMIDINE DERIVATIVE AND METHOD FOR PRODUCING HMG-CoA REDUCTASE INHIBITOR INTERMEDIATE
EP2327682A1 (en)	2009-10-29	2011-06-01	KRKA, D.D., Novo Mesto	Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2373609B1 (en)	2008-12-19	2013-10-16	KRKA, D.D., Novo Mesto	Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
WO2010077062A2 (en) *	2008-12-29	2010-07-08	Hanmi Pharm. Co., Ltd.	Preparation method of statin compound and benzothiazolyl sulfone compound used therein
SI2752407T1 (sl)	2009-01-14	2016-07-29	Krka, Tovarna Zdravil, D.D., Novo Mesto	Kristalni kalcijev rosuvastatin trihidrat
WO2010089770A2 (en)	2009-01-19	2010-08-12	Msn Laboratories Limited	Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
KR101157314B1 (ko) *	2009-06-05	2012-06-15	주식회사종근당	로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법
US8987444B2 (en)	2010-01-18	2015-03-24	Msn Laboratories Private Limited	Process for the preparation of amide intermediates and their use thereof
WO2011104725A2 (en)	2010-02-23	2011-09-01	Cadila Healthcare Limited	Hmg-coa reductase inhibitors and process for the preparation thereof
WO2012011129A2 (en) *	2010-07-22	2012-01-26	Msn Laboratories Limited	Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
WO2012073256A1 (en)	2010-11-29	2012-06-07	Cadila Healthcare Limited	Salts of rosuvastatin
ES2601479T3 (es)	2011-01-18	2017-02-15	Dsm Sinochem Pharmaceuticals Netherlands B.V.	Proceso para la preparación de diolsulfonas
SI2665721T1 (sl)	2011-01-18	2015-10-30	Dsm Sinochem Pharmaceuticals Netherlands B.V.	Metiltetrazol sulfidi in sulfoni
CN103313983B (zh) *	2011-01-18	2016-06-29	中化帝斯曼制药有限公司荷兰公司	在碱存在下制备他汀类化合物的方法
WO2012172564A1 (en) *	2011-05-25	2012-12-20	Dr. Reddy's Laboratories Limited	Process for preparation of rosuvastatin calcium
EP2788342B1 (en)	2011-12-09	2018-01-24	DSM Sinochem Pharmaceuticals Netherlands B.V.	Process for the preparation of a statin precursor
WO2013083719A1 (en)	2011-12-09	2013-06-13	Dsm Sinochem Pharmaceuticals Netherlands B.V.	Process for the preparation of a thioprecursor for statins
KR20130087153A (ko) *	2012-01-27	2013-08-06	코오롱생명과학 주식회사	로수바스타틴의 제조방법 및 이에 사용되는 중간체 화합물
CN103232398B (zh) *	2012-04-28	2016-04-06	上海科州药物研发有限公司	一种瑞舒伐他汀氨基酸盐及其制备方法和应用
KR101292743B1 (ko) *	2012-05-17	2013-08-02	(주) 에프엔지리서치	신규한 스타틴 중간체 및 이를 이용한 피타바스타틴, 로수바스타틴, 세리바스타틴 및 플루바스타틴의 제조 방법
CN103864697A (zh) *	2012-12-11	2014-06-18	润泽制药(苏州)有限公司	瑞舒伐中间体主链醇的制备方法
WO2014108795A2 (en)	2013-01-10	2014-07-17	Aurobindo Pharma Limited	An improved process for the preparation of chiral diol sulfones and statins
CN103420919B (zh) *	2013-08-22	2015-07-08	南京欧信医药技术有限公司	一种嘧啶类衍生物的合成方法
WO2015037018A1 (en) *	2013-09-14	2015-03-19	Ind-Swift Laboratories Limited	Process for the preparation of rosuvastatin via novel intermediates
EP3115367B1 (en)	2014-03-07	2017-11-01	Asymchem Laboratories (Tianjin) Co., Ltd.	Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium therefrom
CN103936680B (zh) *	2014-04-18	2016-08-24	润泽制药(苏州)有限公司	瑞舒伐他汀钙已知杂质的制备方法
CN104788387A (zh) *	2015-04-17	2015-07-22	浙江海森药业有限公司	高纯度瑞舒伐他汀钙的制备方法
KR20160126700A (ko)	2015-04-24	2016-11-02	미래파인켐 주식회사	스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법
CN105461636A (zh) *	2015-12-30	2016-04-06	安徽美诺华药物化学有限公司	一种瑞舒伐他汀甲酯的合成方法
CN106478518A (zh) *	2016-09-27	2017-03-08	南通常佑药业科技有限公司	一种庚烯酸环戊酯衍生物的制备方法
KR101953575B1 (ko)	2016-10-24	2019-05-24	한양대학교 에리카산학협력단	스타틴계 고지혈증 치료제 합성을 위한 새로운 중간체 합성 및 이를 이용한 로수바스타틴 합성 공정 개발
CN108997324A (zh) *	2018-08-21	2018-12-14	南京欧信医药技术有限公司	瑞舒伐他汀钙中间体的制备方法
CN109651259B (zh) *	2018-12-29	2020-05-19	浙江永太科技股份有限公司	一种瑞舒伐他汀钙关键中间体的纯化方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3741509A1 (de)	1987-12-08	1989-06-22	Hoechst Ag	Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
JP2648897B2 (ja)	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
JPH06329679A (ja) *	1993-01-20	1994-11-29	Nissan Chem Ind Ltd	光学活性β−アミノアルコキシボラン錯体
FR2741620B1 (fr) *	1995-11-28	1997-12-26	Oreal	Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
US6260440B1 (en) *	1999-12-17	2001-07-17	Caterpillar Inc.	Method and apparatus for shifting ranges in a continuously variable transmission

1999
- 1999-02-17 GB GBGB9903472.0A patent/GB9903472D0/en not_active Ceased
2000
- 2000-02-15 AR ARP000100642A patent/AR022600A1/es active IP Right Grant
- 2000-02-15 BR BRPI0008301A patent/BRPI0008301B8/pt not_active IP Right Cessation
- 2000-02-15 DK DK00903810T patent/DK1155015T3/da active
- 2000-02-15 PT PT00903810T patent/PT1155015E/pt unknown
- 2000-02-15 ES ES00903810T patent/ES2316349T3/es not_active Expired - Lifetime
- 2000-02-15 WO PCT/GB2000/000481 patent/WO2000049014A1/en not_active Ceased
- 2000-02-15 AU AU25573/00A patent/AU760145B2/en not_active Expired
- 2000-02-15 AT AT00903810T patent/ATE415398T1/de active
- 2000-02-15 TR TR2001/02360T patent/TR200102360T2/xx unknown
- 2000-02-15 US US09/913,539 patent/US6844437B1/en not_active Expired - Lifetime
- 2000-02-15 CN CNB008037043A patent/CN1145625C/zh not_active Expired - Lifetime
- 2000-02-15 SK SK1183-2001A patent/SK286988B6/sk not_active IP Right Cessation
- 2000-02-15 CA CA002362594A patent/CA2362594C/en not_active Expired - Fee Related
- 2000-02-15 DE DE60040905T patent/DE60040905D1/de not_active Expired - Lifetime
- 2000-02-15 MX MXPA01008235A patent/MXPA01008235A/es active IP Right Grant
- 2000-02-15 PL PL350185A patent/PL218518B1/pl unknown
- 2000-02-15 EE EEP200900043A patent/EE05531B1/xx unknown
- 2000-02-15 EE EEP200100430A patent/EE05150B1/xx unknown
- 2000-02-15 IL IL14479300A patent/IL144793A0/xx not_active IP Right Cessation
- 2000-02-15 NZ NZ513261A patent/NZ513261A/en not_active IP Right Cessation
- 2000-02-15 JP JP2000599753A patent/JP2003518474A/ja not_active Withdrawn
- 2000-02-15 KR KR1020017010439A patent/KR100648160B1/ko not_active Expired - Lifetime
- 2000-02-15 CZ CZ20012930A patent/CZ299844B6/cs not_active IP Right Cessation
- 2000-02-15 TR TR2004/01874T patent/TR200401874T2/xx unknown
- 2000-02-15 RU RU2001125421/04A patent/RU2243969C2/ru active
- 2000-02-15 HU HU0200301A patent/HU229835B1/hu unknown
- 2000-02-15 SI SI200031016T patent/SI1155015T1/sl unknown
- 2000-02-15 HK HK02103022.4A patent/HK1041265B/en not_active IP Right Cessation
- 2000-02-15 EP EP00903810A patent/EP1155015B1/en not_active Expired - Lifetime
- 2000-03-10 TW TW089104365A patent/TWI285202B/zh not_active IP Right Cessation
2001
- 2001-07-31 IS IS6029A patent/IS2709B3/is unknown
- 2001-08-02 ZA ZA200106370A patent/ZA200106370B/xx unknown
- 2001-08-16 NO NO20013994A patent/NO320739B1/no not_active IP Right Cessation
2003
- 2003-07-02 US US10/610,700 patent/US6784171B2/en not_active Expired - Lifetime
- 2003-11-12 CL CL200302336A patent/CL2003002336A1/es unknown
2004
- 2004-08-05 IL IL163375A patent/IL163375A/en not_active IP Right Cessation
2007
- 2007-05-08 JP JP2007123108A patent/JP4130844B2/ja not_active Expired - Lifetime
2008
- 2008-03-17 JP JP2008067100A patent/JP2008255114A/ja active Pending
2009
- 2009-01-29 CY CY20091100107T patent/CY1108733T1/el unknown

Also Published As

Publication number	Publication date
HU229835B1 (en)	2014-09-29
TWI285202B (en)	2007-08-11
CZ20012930A3 (cs)	2001-11-14
JP2007291113A (ja)	2007-11-08
NO20013994L (no)	2001-10-16
WO2000049014A1 (en)	2000-08-24
EE200900043A (et)	2010-02-15
RU2243969C2 (ru)	2005-01-10
KR100648160B1 (ko)	2006-11-24
JP2003518474A (ja)	2003-06-10
IL163375A (en)	2008-12-29
HK1041265A1 (en)	2002-07-05
CN1340052A (zh)	2002-03-13
EP1155015A1 (en)	2001-11-21
NO20013994D0 (no)	2001-08-16
IS6029A (is)	2001-07-31
HK1041265B (en)	2009-07-03
ZA200106370B (en)	2002-11-04
CY1108733T1 (el)	2014-04-09
US20040049036A1 (en)	2004-03-11
US6844437B1 (en)	2005-01-18
CN1145625C (zh)	2004-04-14
IS2711B (is)	2011-01-15
GB9903472D0 (en)	1999-04-07
BR0008301B1 (pt)	2013-01-22
DE60040905D1 (de)	2009-01-08
CL2003002336A1 (es)	2005-01-14
JP4130844B2 (ja)	2008-08-06
PL218518B1 (pl)	2014-12-31
ATE415398T1 (de)	2008-12-15
SK286988B6 (sk)	2009-08-06
IS2709B3 (is)	2011-01-15
AU760145B2 (en)	2003-05-08
PT1155015E (pt)	2009-01-27
CZ299844B6 (cs)	2008-12-10
TR200102360T2 (tr)	2001-12-21
SK11832001A3 (sk)	2002-01-07
HUP0200301A2 (en)	2002-08-28
BR0008301A (pt)	2002-01-22
BRPI0008301B8 (pt)	2021-05-25
TR200401874T2 (tr)	2004-10-21
DK1155015T3 (da)	2009-03-02
NO320739B1 (no)	2006-01-23
JP2008255114A (ja)	2008-10-23
EE200100430A (et)	2002-12-16
US6784171B2 (en)	2004-08-31
MXPA01008235A (es)	2002-04-24
ES2316349T3 (es)	2009-04-16
EE05150B1 (et)	2009-04-15
PL350185A1 (en)	2002-11-18
CA2362594C (en)	2009-06-02
KR20010102207A (ko)	2001-11-15
EE05531B1 (et)	2012-04-16
NZ513261A (en)	2003-10-31
EP1155015B1 (en)	2008-11-26
HUP0200301A3 (en)	2004-03-29
CA2362594A1 (en)	2000-08-24
AU2557300A (en)	2000-09-04
SI1155015T1 (sl)	2009-04-30
AR022600A1 (es)	2002-09-04

Publication	Publication Date	Title
IL144793A0 (en)	2002-06-30	Process for the production of tert-butyl (e)-(6-[2[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl] (4r,6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate
PT1263739E (pt)	2008-02-19	''sais cristalinos do ácido 7-[4-(4-fluorofenil)-6-isopropil-2- [metil(metilsulfonil)amino]pirimidin-5-il]-(3r,5s)-3,5-di-hidroxihept- 6-enóico''
IL175086A0 (en)	2006-08-20	Process for the manufacture of the calcium salt of rosuvastatin (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl) amino]pyrimidin-5-yl] 3r,5s)- 3,5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
NO20040122L (no)	2004-01-12	Fremgangsmåte for fremstilling av aminopyrimidinforbindelser samt pyrimidinforbindelser
IL158588A0 (en)	2004-05-12	Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) - methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinase inhibitors
HUP0104828A3 (en)	2002-10-28	Crystalline bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-1,5-dihydroxyhept-6-enoic acid]calcium salt, pharmaceutical composition containing it and process for its preparation
DK1897546T3 (da)	2011-01-17	Kombinerede sammensætninger omfattende (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s]-3,5-dihydroxyhept-6-enoinsyre
PT1185274E (pt)	2005-03-31	Composicoes de farmacos contendo acido (e) - 7- [4-(4-fluorofenil)- 6-isopropil-2-[metil ( metilsulfonil)amino] pirimidin-5-il] (3r,5s) -di-hidroxi-hept-6-enoico e um inibidor, indutor ou substrato da isoenzima p450 3a4
WO2003002580A8 (en)	2003-01-30	6-`2-(phosphonomethoxy)alkoxy pyrimidine derivatives having antiviral activity
IL153662A0 (en)	2003-07-06	Process for the preparation of 4,6-dimethoxy-2- (methylsulfonyl)-1,3-pyrimidine
FI952287A7 (fi)	1995-11-14	Menetelmä 2-amino-4,6-dikloori-pyrimidiinin valmistamiseksi
FI942159L (fi)	1994-11-11	Menetelmä 2-(4-(4-(4-kloori-1-pyratsolyyli)butyyli)-1-piperatsinyyli)pyrimidiinin (lesopitron) valmistamiseksi
CZ20012431A3 (cs)	2003-02-12	Způsob výroby (4R,6R)tert-butyl[6-(2-aminoethyl)-2,2-dimethyl[1,3]dioxan-4-yl]acetatu a meziproduktů pro jeho výrobu
AU6434900A (en)	2001-02-19	Method for the production of 4,6-dichloropyrimidine with the aid of phosgene
IL144491A0 (en)	2002-05-23	Process for the preparation of 6-(perfluoroalkyl) uracil compounds
AU3231500A (en)	2000-09-04	Process for the preparation of 6-(perfluoroalkyl) uracil compounds from urea compounds
HK1060256A (en)	2004-08-06	Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
AU1657900A (en)	2000-06-26	Process for the preparation of pyrimidinone derivatives
HK1063430A (en)	2004-12-31	6-[2-(phosphonomethoxy)alkoxy]pyrimidine derivatives having antiviral activity

Legal Events

Date	Code	Title
2005-03-20	FF	Patent granted
2005-05-17	KB	Patent renewed
2006-04-10	KB	Patent renewed
2010-06-30	KB	Patent renewed
2014-01-30	KB	Patent renewed
2018-01-31	KB	Patent renewed
2020-09-30	EXP	Patent expired